Harsoyo Agus, Eri Rifqi Rizkani, Zahrani Sania, Balweel Haikal, Tafriend Novaro Adeneur
Department of Cardiology, Gatot Soebroto Army Central Hospital, Jakarta, Indonesia.
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Stem Cell Rev Rep. 2025 Oct;21(7):2066-2088. doi: 10.1007/s12015-025-10952-2. Epub 2025 Jul 29.
Cardiac arrhythmias remain a major global health concern despite advances in therapeutic strategies. In certain clinical contexts, novel and minimally invasive therapies are particularly desirable. Exosomes have emerged as a promising approach for various diseases, but their therapeutic role in arrhythmias remains underexplored. This systematic review aims to synthesize and evaluate current evidence on the potential of exosome-based therapy for cardiac arrhythmias.
A comprehensive literature search was conducted in PubMed, ScienceDirect, and SCOPUS in accordance with PRISMA guidelines, using the search terms: (exosome) AND ((cardiac conduction) OR (arrhythmia)). Studies were included if they investigated the acute or mid-term effects of exosome therapy on cardiac conduction or arrhythmia incidence in animal models, and reported at least one relevant electrophysiological or arrhythmic outcome. Descriptive studies, biomarker-only evaluations, and studies not examining exosomes as a therapeutic intervention were excluded.
The initial search yielded 759 articles (259 from PubMed, 394 from SCOPUS, 106 from ScienceDirect). After removing 68 duplicates and screening titles and abstracts, 77 articles were selected for full-text review. Eighteen studies met the inclusion criteria. Most reported favorable outcomes, including reduced arrhythmia inducibility, improved or restored cardiac conduction, and enhanced overall cardiac function.
Preclinical evidence suggests that exosome therapy is potentially effective in reducing arrhythmia burden and improving cardiac electrophysiology, with a favorable safety profile in animal models. Further research is needed to understand its mechanisms deeper, optimize delivery methods, and assess its applicability in human populations.
尽管治疗策略取得了进展,但心律失常仍然是全球主要的健康问题。在某些临床情况下,新颖且微创的治疗方法尤为可取。外泌体已成为治疗各种疾病的一种有前景的方法,但其在心律失常中的治疗作用仍未得到充分探索。本系统综述旨在综合和评估当前关于基于外泌体的心律失常治疗潜力的证据。
根据PRISMA指南,在PubMed、ScienceDirect和SCOPUS中进行了全面的文献检索,检索词为:(外泌体)AND((心脏传导)或(心律失常))。如果研究调查了外泌体治疗对动物模型心脏传导或心律失常发生率的急性或中期影响,并报告了至少一项相关的电生理或心律失常结果,则纳入研究。排除描述性研究、仅生物标志物评估以及未将外泌体作为治疗干预措施的研究。
初步检索得到759篇文章(259篇来自PubMed,394篇来自SCOPUS,106篇来自ScienceDirect)。去除68篇重复文章并筛选标题和摘要后,77篇文章被选入全文综述。18项研究符合纳入标准。大多数研究报告了良好的结果,包括心律失常诱导性降低、心脏传导改善或恢复以及整体心脏功能增强。
临床前证据表明,外泌体治疗在减轻心律失常负担和改善心脏电生理方面可能有效,在动物模型中具有良好的安全性。需要进一步研究以更深入地了解其机制、优化递送方法并评估其在人群中的适用性。